Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire•12/11/2026•16:35 ET
1
Key Highlights
- ➤Phase 3 LEGACY kidney-transplant trial remains on track to initiate in Q4 2026
- ➤FDA cleared registrational-path IND for tegoprubart in islet-cell transplantation
- ➤FDA granted Fast Track designation for kidney-transplant rejection prevention
- ➤Cash, equivalents and short-term investments $69.7M; runway extends into Q2 2027
- ➤Q3 net loss $3.9M, including a $17.0M non-cash warrant-liability gain
Expert Statements
David-Alexandre C. Gros, Chief Executive Officer of Eledon Pharmaceuticals
“We continue to execute across our key strategic priorities and make meaningful progress in the tegoprubart clinical program across multiple transplant types, including plans to initiate our global Phase 3 LEGACY trial in kidney transplantation by year end”
David-Alexandre C. Gros, Chief Executive Officer of Eledon Pharmaceuticals
“New patient-reported outcomes data from the Phase 2 BESTOW program further strengthened the evidence supporting tegoprubart’s differentiated profile compared to today’s standard of care immunosuppression therapy, while investigator-initiated studies and compassionate-use protocols help expand our understanding of tegoprubart and its therapeutic potential in different transplant settings where significant unmet needs remain.”
Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to initiate in Q4 2026
FDA cleared the Company’s IND application for a planned registrational path study of tegoprubart in islet cell transplantation for patients with type 1 diabetes
Get started
Create a free account to read the full story.